Funding sources: Eli Lilly and Company.

Conflicts of interest: Dr. Andrew Blauvelt had received honoraria as a scientific adviser/clinical study investigator from AbbVie, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma, but none related to this work. Dr. Nianwen Shi, Dr. Carolyn R. Lew, and Nicole M. Zimmerman, are employees of IBM Watson Health that was compensated by Eli Lilly and Company for conducting this research. Dr. Najwa Somani, Dr. Russel Burge, Dr. Baojin Zhu, Terri Ridenour, Bilal Atiya, and Dr. Mwangi J. Murage are employees of Eli Lilly and Company and hold stock in Eli Lilly and Company.

IRB approval status: Not applicable. All study data were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). As all databases used in the study are fully de-identified and compliant with the HIPPA, this study was exempted from Institutional Review Board approval.

Some of the data on this manuscript have been presented in a poster at the 2020 PAs & NPs Fall Clinical Dermatology Conference, November 13-15, Orlando, Florida, and at the 2020 Las Vegas Dermatology Seminar, Nov 20-21, Las Vegas, Nevada.